Charles Schwab
ZNTL icon

Charles Schwab’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Charles Schwab’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Buy
171,911
+120,824
+237% +$482K ﹤0.01% 3057
2026
Q1 		$120K Buy
+51,087
New +$132K ﹤0.01% 3362
2025
Q4 		– Sell
-41,981
Closed -$63.4K – 3516
2025
Q3 		$63.4K Sell
41,981
-257,116
-86% -$385K ﹤0.01% 3413
2025
Q2 		$347K Sell
299,097
-187,402
-39% -$247K ﹤0.01% 3273
2025
Q1 		$774K Sell
486,499
-10,863
-2% -$23.4K ﹤0.01% 2933
2024
Q4 		$1.51M Buy
497,362
+91,152
+22% +$299K ﹤0.01% 2766
2024
Q3 		$1.49M Sell
406,210
-62,203
-13% -$226K ﹤0.01% 2793
2024
Q2 		$1.92M Buy
468,413
+12,476
+3% +$139K ﹤0.01% 2717
2024
Q1 		$7.19M Buy
455,937
+10,114
+2% +$139K ﹤0.01% 2153
2023
Q4 		$6.75M Buy
445,823
+3,759
+0.9% +$54.8K ﹤0.01% 2185
2023
Q3 		$8.87M Buy
442,064
+36,219
+9% +$919K ﹤0.01% 1978
2023
Q2 		$11.4M Buy
405,845
+72,277
+22% +$1.73M ﹤0.01% 1851
2023
Q1 		$5.74M Sell
333,568
-2,189
-0.7% -$44.3K ﹤0.01% 2138
2022
Q4 		$6.76M Buy
335,757
+12,254
+4% +$264K ﹤0.01% 2050
2022
Q3 		$7.01M Buy
323,503
+2,960
+0.9% +$80.9K ﹤0.01% 2038
2022
Q2 		$9.01M Buy
320,543
+52,706
+20% +$1.4M ﹤0.01% 1893
2022
Q1 		$12.4M Buy
267,837
+6,831
+3% +$368K ﹤0.01% 1831
2021
Q4 		$21.9M Buy
261,006
+8,456
+3% +$654K 0.01% 1507
2021
Q3 		$16.8M Buy
252,550
+98,286
+64% +$5.67M 0.01% 1709
2021
Q2 		$8.21M Buy
154,264
+25,419
+20% +$1.36M ﹤0.01% 2101
2021
Q1 		$5.59M Buy
128,845
+4,357
+3% +$188K ﹤0.01% 2242
2020
Q4 		$6.47M Buy
124,488
+37,817
+44% +$1.71M ﹤0.01% 2089
2020
Q3 		$2.83M Buy
86,671
+20,866
+32% +$731K ﹤0.01% 2364
2020
Q2 		$3.16M Buy
+65,805
New +$2.52M ﹤0.01% 2253

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Charles Schwab's ZNTL Position: Q2 2026 in Review

Charles Schwab increased its Zentalis Pharmaceuticals (ZNTL) stake by 237% in Q2 2026, buying an estimated $482K and bringing the position to 171,911 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #3057.

Charles Schwab first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $21.9M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Charles Schwab held 171,911 shares of Zentalis Pharmaceuticals worth $834K as of Q2 2026.
  • Charles Schwab bought 120,824 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $482K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3057 holding.
  • Charles Schwab first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Charles Schwab's Zentalis Pharmaceuticals position peaked at $21.9M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.